Can the new CMS Updates Help Employers with Drug Cost Reporting and Savings?

Rule Changes Coming to CMS
Many employers self-fund and go at risk for drug costs, and this gives them more control. But for years now, the rising cost of medication has caused employers significant grief. There may finally be some help from the Centers for Medicare and Medicaid Services (CMS). In 2019, the CMS got serious about transparency and introduced a new rule requiring health plans to report the cost of prescription drugs on an annual basis.

Share This Post

We think so.

Many employers self-fund and go at risk for drug costs, and this gives them more control. But for years now, the rising cost of medication has caused employers significant grief. There may finally be some help from the Centers for Medicare and Medicaid Services (CMS). In 2019, the CMS got serious about transparency and introduced a new rule requiring health plans to report the cost of prescription drugs on an annual basis. The thinking was that more transparency on costs would allow employers to identify areas where cost savings could be achieved. That didn’t happen.

The first round of reporting was chaotic and challenging for employers, and this did not lead to an era of transparency. For the second round, everyone is more hopeful because the CMS introduced several updates to the rule, including new reporting requirements and increased flexibility that should help employers.

Note the most significant change is the addition of a new data element that requires health plans to report the total number of prescriptions filled for each covered drug. This is designed to give employers a bird’s eye view into how often their employees use specific drugs, which could allow them better negotiate with the drug company for rebates or preferred pricing.

Another big change is the addition of alternative methodologies for reporting. For example, employers may now use a “simple average” of drug prices rather than a weighted average, making the calculations a little easier. Additionally, plans with fewer than 500 covered lives will now be able to report drug costs at a higher level of aggregation to simplify reporting for small employers.

Only time will tell, though. The first round did not go smoothly, but CMS listened to the feedback and used it to make meaningful changes. The second round will undoubtedly go better than round one, but it is important to note that this isn’t the single solution to high drug costs. Employers will still need to take a proactive approach to managing their pharmacy budgets using technology that helps prescribers understand what the lowest-cost drug for their patient is based on the employer’s formulary.  

More To Explore

Article

A New Way to Manage the GLP-1 Explosion

GLP-1 receptor agonists are all the rage these days for the promise of easy weight loss. GLP1s are FDA-approved for managing Type 2 diabetes but physicians are prescribing the medication for off-label use to help their patients lose weight. Between 2020 and 2023, the use of GLP-1 medications such as Ozempic and Wegovy, increased sharply due to off-label prescriptions. While these medications are very effective, they are also very expensive, which is challenging insurers, employers, and patients alike. As the demand for GLP-1 drugs continues to grow, particularly for weight loss, understanding the complexities of coverage and finding cost-saving strategies has become a top priority.

Article

The Promise of Precision Medicine

In the U.S., medical treatment is based on the diagnosis, not the person. It’s a one-size-fits-all approach in which physicians prescribe medications that have been approved to treat the disease state. The approach has improved lives for many but not all. Recently, a new approach to pharmacology is developing, precision medicine, which tailors a treatment to an individual’s biology.

Ready to Get Started?

We're Here

To Help You Save

And, we are waiting…
Contact us, and we will be more than happy to answer all of your questions.